Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s12094-019-02075-1.pdf
Reference128 articles.
1. Ofuji K, Tada Y, Yoshikawa T, Shimomura M, Yoshimura M, Saito K, Nakamoto Y, Nakatsura T. A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer. Int J Oncol. 2015;46(2):497–504.
2. Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME. The Surveillance, epidemiology, and end results (SEER) program and pathology. Am J Surg Pathol. 2016;40(12):e94–102.
3. Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Chirieac LR, D’Amico TA, Demmy TL, Feigenberg SJ, Grannis FJ, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Robert F, Sugarbaker DJ, Wood DE. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006;4(6):548–82.
4. Wu M, Yuan Y, Pan YY, Zhang Y. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells. Mol Med Rep. 2014;9(6):2417–22.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–8.
Cited by 73 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Anticancer effect of covalent purine-containing EGFR TKI, ZZC4 and its mechanism of action through network pharmacology;Life Sciences;2024-01
2. Aptamer-Functionalized ZIF-8 Nanomedicine for Targeted Delivery of Gefitinib and siRNA to Treat Tyrosine-Kinase-Inhibitor-Resistant Nonsmall-Cell Lung Cancer;ACS Applied Nano Materials;2023-11-18
3. Circumvention of Gefitinib Resistance by Repurposing Flunarizine via Histone Deacetylase Inhibition;ACS Pharmacology & Translational Science;2023-09-28
4. Rucaparib inhibits lung adenocarcinoma cell proliferation and migration via the SHCBP1/CDK1 pathway;The FEBS Journal;2023-08-28
5. Smart Sensors and Microtechnologies in the Precision Medicine Approach against Lung Cancer;Pharmaceuticals;2023-07-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3